Clinical Trials
6
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 2
5 (83.3%)Phase 1
1 (16.7%)Clinical Study of CVL006 Injection in Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: CVL006 Injection
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Convalife (Shanghai) Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06621615
Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Convalife (Shanghai) Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06519110
Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases
Phase 2
Not yet recruiting
- Conditions
- Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Convalife (Shanghai) Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT06374888
CVL237 Tablets for APDS/PASLI
Phase 2
Not yet recruiting
- Conditions
- PI3K and P110delta Hyperactivation Syndrome
- Interventions
- Drug: CVL237 placebo tabletsDrug: CVL237 tablets
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Convalife (Shanghai) Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT06293716
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
Phase 2
Not yet recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: CVL237 tablets
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Convalife (Shanghai) Co., Ltd.
- Target Recruit Count
- 98
- Registration Number
- NCT06183736
- Locations
- 🇨🇳
Li Ning, Beijing, Beijing, China
- Prev
- 1
- 2
- Next
News
No news found